Limited Availability: $799 preorder (reg. $1,299). Save $500. Reserve for $49 →
Home
The Science
Cancer
How It Works
Pricing
About
Contact
EN FR DE 简体 繁體
Reserve Your Test for $49
Golden sunrise over the Ottawa River with Parliament Hill silhouetted against warm sky

About miRoncol Health

An Ottawa-based health technology company building Canada's first microRNA multi-disease screening (MMDS) platform. Today, miCheckup detects suspected cancer signals. Tomorrow, the same science may extend far beyond.

Reserve Your Test for $49

Preorder $799 · Regular $1,299 · Save $500

Home › About Us
Why We Exist Our Team The Vision Reserve for $49
Why We Exist

Canada screens for very few cancers. We believe Canadians deserve better.

miRoncol Health was founded on a simple observation: the gap between what Canada screens for and what kills Canadians is unconscionable.

Canada's public healthcare system provides organized cancer screening for very few cancer types — breast, cervical, and colorectal. The remaining cancers — including the #1 cancer killer (lung) — have no population-level early detection pathway.1

miRoncol Health was founded to close that gap. We developed miCheckup — a microRNA multi-cancer early detection (MCED) test that analyzes circulating microRNA patterns associated with multiple solid tumor cancers from a single blood draw. Our approach is built on Nobel Prize-recognized science, peer-reviewed research, and a commitment to making advanced screening accessible to every Canadian.23

We are not a replacement for the public system. We are a complement to it — filling the gap where no screening exists.

How miCheckup Works
Person in a warm modern medical consultation setting conveying trust and accessibility
The Vision

From MCED to MMDS — a platform for the future of screening.

miCheckup is an MCED test today. The microRNA multi-disease screening (MMDS) platform it's built on is designed to go further.

microRNA patterns don't just change with cancer — they change with all disease. Peer-reviewed research has documented microRNA signature changes in cardiovascular disease, neurodegenerative diseases, and dozens of other conditions.

miRoncol Health is actively exploring research partnerships in cardiovascular health and neurological health, with the goal of expanding the MMDS platform beyond cancer in the future. The microRNA data captured in your miCheckup test today contains thousands of molecular data points — far more than the current cancer panel analyzes. As the science advances, that same data may yield new health insights.

Today, miCheckup is a multi-cancer early detection test — and that's what we sell. The MMDS vision is where the science is heading, and we're building the platform to get there.

Explore the Science
Modern research laboratory with advanced molecular sequencing equipment

Our Leadership Team

Victoria Xu, Co-Founder & CEO of miRoncol Health

Victoria Xu

Co-Founder & CEO

Victoria leads miRoncol Health's business strategy, operations, and go-to-market execution. Her vision for democratizing cancer screening drives the company's mission to make molecular early detection accessible to every Canadian.

Hai Hu PhD, Co-Founder & Chief Scientific Officer of miRoncol Health

Hai Hu, PhD

Co-Founder & Chief Scientific Officer

Dr. Hu is the scientific architect behind miCheckup's microRNA testing technology. His peer-reviewed research on blood-based microRNA diagnostics for multi-cancer early detection forms the foundation of the miCheckup platform.

Christopher M. Gallagher MD, Co-Founder & CMO of miRoncol Health

Christopher M. Gallagher, MD

Co-Founder & Chief Medical Officer · Medical Oncologist

Dr. Gallagher is a practicing medical oncologist with over 20 years of experience in breast cancer treatment and clinical research. A graduate of Georgetown University School of Medicine, he has led major clinical trial programs and guides the company's clinical strategy.

Gilles Erb PhD, Medical & Scientific Director of miRoncol Health

Gilles Erb, PhD

Medical & Scientific Director

Dr. Erb oversees miRoncol Health's clinical and scientific programs, including the advancement of the MMDS platform across cancer and future disease applications of microRNA testing.

What Guides Us

Our values.

The principles that drive every decision at miRoncol Health.

Contact Us
Aerial view of Canadian landscape with forests and waterways

Science First

Read Less
Every claim we make is grounded in peer-reviewed research. We don't oversell, overclaim, or oversimplify. We let the science speak for itself.

Built in Ottawa. Built for Canada. Built to close the screening gap.

miCheckup screens for multiple solid tumor cancers from a single blood draw. Available now in Ontario.

Reserve Your Test for $49

Preorder $799 · Regular $1,299 · Save $500

Important Safety Information

+

miCheckup is intended for adults at or above the age of majority in their province (18 or older in most provinces; 19 or older in British Columbia, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, and Yukon). miCheckup is a multi-cancer early detection (MCED) test — an early warning test intended to identify a suspected cancer signal associated with multiple solid tumor cancers from a single blood draw. miCheckup does not detect all cancers and should be used in addition to routine cancer screening tests recommended by your healthcare provider.

Use of miCheckup is not recommended in individuals who are pregnant or planning pregnancy, under the age of majority in their province, currently undergoing active cancer treatment, or currently experiencing symptoms that may indicate cancer. If you are experiencing symptoms, please consult your physician directly.

Results should be interpreted by a healthcare provider in the context of your medical history, clinical signs, and symptoms. All miCheckup results are reviewed with you by a physician. A result of "no suspected cancer signal identified" does not rule out cancer. A result of "suspected cancer signal identified" is not a diagnosis — it requires confirmatory diagnostic evaluation by medically established procedures, which is why a whole-body MRI and physician follow-up are included in your miCheckup test.

If a suspected cancer signal is identified but cancer is not confirmed with further testing, it could mean that cancer is not present, or that testing was insufficient to detect cancer — including due to the cancer being located in an area or of a type not well represented in the miCheckup signal. False positive results (a suspected cancer signal identified when cancer is not present) and false negative results (no suspected cancer signal identified when cancer is present) do occur.

miCheckup is a complement to, not a replacement for, standard cancer screening programs. Continue all recommended screening — including mammography, Pap/HPV testing, and colorectal screening (FIT or colonoscopy) — as directed by your healthcare provider. Cancer diagnosis in Canada always requires a tissue biopsy confirmed by a pathologist. If a suspected cancer signal is identified, imaging and clinical workup by your healthcare team will determine the actual status. Many findings turn out to be benign after further investigation.

Laboratory/Test Information

+

miCheckup is a multi-cancer early detection (MCED) Laboratory-Developed Test (LDT), performed at an accredited Canadian medical laboratory certified by the Institute for Quality Management in Healthcare (IQMH). In Canada, LDTs are regulated as a clinical laboratory service under provincial and territorial laboratory oversight. Your blood sample is collected, processed, and analyzed entirely within Canada.

The miCheckup microRNA analysis is based on peer-reviewed research published in Scientific Reports (Nature Portfolio, 2024) and Cancers (MDPI, 2022), validated on thousands of peer-reviewed blood samples, with ongoing validation through the Ontario Health Study using 4,000+ Canadian blood samples.

Published validation shows greater than 99% specificity and greater than 90% sensitivity for the majority of cancer types in the current miCheckup panel of multiple solid tumor cancers. Performance may vary by cancer type and individual factors. For a detailed breakdown of sensitivity and specificity by cancer type, and the complete list of cancers currently in the miCheckup panel, visit The Science.

All personal health data is stored in Canada and handled in accordance with the Personal Information Protection and Electronic Documents Act (PIPEDA) and applicable provincial health privacy legislation, including the Personal Health Information Protection Act (PHIPA) in Ontario.

miCheckup is currently available in Ontario, expanding across Canada. For the full safety, regulatory, and performance disclosure, see Important Information.

References

+
  1. Canadian Cancer Society. Canadian Cancer Statistics 2024. cancer.ca/statistics
  2. Zhang J, Rui H, Hu H. "Noninvasive multi-cancer detection using blood-based cell-free microRNAs." Scientific Reports 14, 22136 (2024). doi.org
  3. Zhang A, Hu H. "A Novel Blood-Based microRNA Diagnostic Model with High Accuracy for Multi-Cancer Early Detection." Cancers 14(6), 1450 (2022). doi.org